Compare SPCE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPCE | MOLN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.9M | 157.8M |
| IPO Year | N/A | 2021 |
| Metric | SPCE | MOLN |
|---|---|---|
| Price | $2.99 | $4.09 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.22 | $3.75 |
| AVG Volume (30 Days) | ★ 3.8M | 2.3K |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,661,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,656.89 | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $3.36 |
| 52 Week High | $6.82 | $5.91 |
| Indicator | SPCE | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 46.91 |
| Support Level | $3.71 | $4.13 |
| Resistance Level | $4.57 | $4.57 |
| Average True Range (ATR) | 0.28 | 0.16 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 7.05 | 23.91 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.